Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Cytokinetics in a ...

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years.

Stifel analysts initiated coverage on Cytokinetics shares (NASDAQ:CYTK), assigning a Buy rating and setting a price target of ...

Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC ...

The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the ...

Canaccord Genuity analyst Caitlin Burrows initiated coverage on Orthofix Medical Inc. OFIX with a Buy rating and announced a ...

Fintel reports that on January 22, 2025, Stifel initiated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy recommendation.

Cytokinetics, Incorporated announced the granting of stock options and restricted stock units (RSUs) to nine new employees on December 31, 2024, as part of their employment inducement. The company ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its aspirational Vision 2030 ...

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to ...